News & Opinion
Top 10 Innovations
Cell & Molecular Biology
Disease & Medicine
Ecology & Environment
Genetics & Genomics
Pharma & Biotech
Image of the Day
Week in Review: August 29–September 2
Jef Akst | Sep 2, 2016
Roger Tsien dies; the CRISPR patent dispute you’ve never heard of; immunotherapy for Alzheimer’s; Tasmanian devils developing resistance to transmissible cancer
Student Alleges His Team Didn’t Earn CRISPR Patent
Kerry Grens | Aug 18, 2016
A former researcher at the Broad Institute has suggested the University of California, Berkeley, team deserves credit for inventing the gene-editing technique.
Do Patents Promote or Stall Innovation?
Catherine Offord | May 31, 2016
A petition recently filed with the Supreme Court triggers renewed debate about the role of patents in the diagnostics sector.
CRISPR Patent Investigation to Begin
Jef Akst | Mar 9, 2016
The US Patent and Trademark Office is set to launch its “patent interference” inquiry into the competing patents on the gene-editing technology.
New CRISPR Patent Issued
Jef Akst | Feb 18, 2016
Caribou Biosciences receives a patent related to the gene-editing technology.
Who Owns CRISPR?
Jenny Rood | Apr 3, 2015
With one US patent awarded and many other applications under consideration for the popular genome-editing technology, companies are adopting multiple strategies to navigate the complex intellectual property landscape.
Of Cells and Limits
Anna Azvolinsky | Feb 28, 2015
Leonard Hayflick has been unafraid to speak his mind, whether it is to upend a well-entrenched dogma or to challenge the federal government. At 86, he’s nowhere near retirement.
Keeping Up with IP
Kate Yandell | Aug 31, 2014
It’s never too early to start thinking about intellectual property rights—even for biologists doing basic research.
Patent Plea Ping Pong
Kerry Grens | Aug 21, 2014
A genetic testing firm accused of infringing upon Myriad Genetics’s gene patents fights back in an attempt to wipe other patents out.
Guidelines for Gene Patent Ruling
Jef Akst | Mar 7, 2014
The USPTO offers guidance to its patent examiners on how to interpret the Supreme Court’s rulings in the recent Myriad and Prometheus cases.